ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Dimethylformamide → (1-{2-[5-(9-{2-[1-(2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-3h-imidazol-4-yl}-6-methyl-6,7-dihydro-5h-dibenzo[c,e]azepin-3-yl)-1h-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester

HRID 417406
印刷

反応式

HRID 417406 の反応式
[CH3:1][O:2][C:3](=[O:5])[NH2:4].[NH:6]1[CH2:10][CH2:9][CH2:8][CH:7]1[C:11]1[NH:15][C:14]([C:16]2[CH:17]=[CH:18][C:19]3[C:25]4[CH:26]=[CH:27][C:28]([C:30]5[NH:31][C:32]([CH:35]6[CH2:39][CH2:38][CH2:37][NH:36]6)=[N:33][CH:34]=5)=[CH:29][C:24]=4[CH2:23][N:22]([CH3:40])[CH2:21][C:20]=3[CH:41]=2)=[CH:13][N:12]=1.[CH3:42][O:43][C:44]([NH:46][C@H:47]([C:51]([OH:53])=O)[CH:48]([CH3:50])[CH3:49])=[O:45].CN(C(ON1N=NC2[CH:65]=[CH:66][CH:67]=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.[CH:78](N(C(C)C)CC)(C)C.CN([CH:90]=[O:91])C>CCOC(C)=O>[CH3:1][O:2][C:3](=[O:5])[NH:4][CH:78]([C:90]([N:6]1[CH2:10][CH2:9][CH2:8][CH:7]1[C:11]1[NH:15][C:14]([C:16]2[CH:17]=[CH:18][C:19]3[C:25]4[CH:26]=[CH:27][C:28]([C:30]5[NH:31][C:32]([CH:35]6[CH2:39][CH2:38][CH2:37][N:36]6[C:51](=[O:53])[CH:47]([NH:46][C:44]([O:43][CH3:42])=[O:45])[CH:48]([CH3:49])[CH3:50])=[N:33][CH:34]=5)=[CH:29][C:24]=4[CH2:23][N:22]([CH3:40])[CH2:21][C:20]=3[CH:41]=2)=[CH:13][N:12]=1)=[O:91])[CH:66]([CH3:65])[CH3:67]
参加物実験手順後処理出典と根拠反応ノート

参加物

8

反応物 6

HCID 6228DimethylformamideHCID 11722Methyl CarbamateHCID 81531DiisopropylethylamineHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 10942966(2S)-2-((methoxycarbonyl)amino)-3-methylbutanoic acid
HCID 66620578
3,9-bis-[2-(pyrrolidin-2-yl)-3H-imidazol-4-yl]-6-methyl-6,7-dihydro-5H-dibenzo[c,e]azepine

生成物 1

HCID 66620472(1-{2-[5-(9-{2-[1-(2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-3h-imidazol-4-yl}-6-methyl-6,7-dihydro-5h-dibenzo[c,e]azepin-3-yl)-1h-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester

試薬・触媒・溶媒 1

HCID 8857Ethyl Acetate溶媒

実験手順

1-{2-[5-(9-{2-[1-(2-Methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-6-methyl-6,7-dihydro-5H-dibenzo[c,e]azepin-3-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester: To the solution of 3,9-bis-[2-(pyrrolidin-2-yl)-3H-imidazol-4-yl]-6-methyl-6,7-dihydro-5H-dibenzo[c,e]azepine (25 mg, 0.035 mmol) and MeOCO-Val-OH (13 mg, 0.074 mmol) in DMF (1.2 ml) was added HATU (28 mg, 0.074 mmol), followed by diisopropylethylamine (61 μl, 0.35 mmol). The mixture was stirred for 90 minutes and was diluted with EtOAc. The organic phase was washed with 1 N NaOH solution, water, and brine, and was dried with sodium sulfate. Concentration and purification by HPLC (0.1% TFA/CH3CN/0.1% TFA/H2O) gave (1-{2-[5-(9-{2-[1-(2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-6-methyl-6,7-dihydro-5H-dibenzo[c,e]azepin-3-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (24 mg). m/z: 794.3 (M+H)+, 397.8 (M+2H)+/2. 1H NMR (CD3OD, 300 MHz) δ 8.0-7.9 (8H, m), 5.27 (2H, m), 4.3-4.2 (2H, m), 4.2-3.8 (8H, m), 3.66 (6H, s), 3.08 (3H, s), 2.7-2.5 (2H, m), 2.4-1.9 (8H, m), 0.94-0.90 (12H, m).

後処理

  1. washThe organic phase was washed with 1 N NaOH solution, water, and brine
  2. dry with materialwas dried with sodium sulfate
  3. concentrationConcentration and purification by HPLC (0.1% TFA/CH3CN/0.1% TFA/H2O)

出典と根拠

ORDレコード
ord-28c1322102bc44f9a1748860f6cb0583
出典データセット
uspto-grants-2012_01
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08088368B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート